Mantle cell lymphoma diagnostic study of choice: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(11 intermediate revisions by 2 users not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{Akram}}
{{CMG}}; {{AE}} {{Akram}}
== Overview ==
== Overview ==
Tissue [[biopsy]] (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.


== Diagnostic Study of Choice ==
== Diagnostic Study of Choice ==


=== Study of choice ===
=== Study of choice ===
* Tissue biopsy is the gold standard test for the diagnosis of mantle cell lymphoma.   
* Tissue [[Biopsy punch|biopsy]] (nodal or extranodal) is the gold standard test for the [[diagnosis]] of mantle cell lymphoma.   
* The microscopic histological findings can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']].
*


==== Histology ====
* The [[microscopic]] [[Histological|histological findings]] can be found [[Mantle cell lymphoma pathophysiology #Microscopic Pathology|'''here''']].
==== Immunohistochemistry ====
* [[CD19]], [[CD20]], [[CD22]], [[CD43]], [[CD79a]], [[CD5]], and [[FMC7]] typically are positive, whereas [[CD23]], [[CD10]], [[CD200]], and [[BCL6]] are usually negative.<ref>{{Cite journal
| author = [[Francesco Bertoni]], [[Emanuele Zucca]] & [[Finbarr E. Cotter]]
| title = Molecular basis of mantle cell lymphoma
| journal = [[British journal of haematology]]
| volume = 124
| issue = 2
| pages = 130–140
| year = 2004
| month = January
| pmid = 14687022
}}</ref><ref>{{Cite journal
| author = [[Chan Yoon Cheah]], [[John F. Seymour]] & [[Michael L. Wang]]
| title = Mantle Cell Lymphoma
| journal = [[Journal of clinical oncology : official journal of the American Society of Clinical Oncology]]
| volume = 34
| issue = 11
| pages = 1256–1269
| year = 2016
| month = April
| doi = 10.1200/JCO.2015.63.5904
| pmid = 26755518
}}</ref>
* [[Cyclin D1]] is positive in majority of the cases.
* [[SOX11]] expression is useful if [[cyclin D1]] is negative.
*[[Ki-67]] should also be included in the initial work-up. [[Ki-67]] proliferation index of less than 30% is associated with a favorable [[prognosis]].<ref>{{Cite journal
| author = [[Olaf Determann]], [[Eva Hoster]], [[German Ott]], [[Heinz Wolfram Bernd]], [[Christoph Loddenkemper]], [[Martin Leo Hansmann]], [[Thomas E. F. Barth]], [[Michael Unterhalt]], [[Wolfgang Hiddemann]], [[Martin Dreyling]] & [[Wolfram Klapper]]
| title = Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group
| journal = [[Blood]]
| volume = 111
| issue = 4
| pages = 2385–2387
| year = 2008
| month = February
| doi = 10.1182/blood-2007-10-117010
| pmid = 18077791
}}</ref><ref>{{Cite journal
| author = [[R. Schaffel]], [[C. V. Hedvat]], [[J. Teruya-Feldstein]], [[D. Persky]], [[J. Maragulia]], [[D. Lin]], [[C. S. Portlock]], [[C. H. Moskowitz]] & [[A. D. Zelenetz]]
| title = Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
| journal = [[Annals of oncology : official journal of the European Society for Medical Oncology]]
| volume = 21
| issue = 1
| pages = 133–139
| year = 2010
| month = January
| doi = 10.1093/annonc/mdp495
| pmid = 20019090
}}</ref>
==== Fluorescence in situ hybridization (FISH) ====
* [[FISH]] can be used to detect the [[Chromosomal translocation|translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal
| author = [[Tsieh Sun]], [[Mary Lowery Nordberg]], [[James D. Cotelingam]], [[Diana M. Veillon]] & [[John Ryder]]
| title = Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma
| journal = [[American journal of hematology]]
| volume = 74
| issue = 1
| pages = 78–84
| year = 2003
| month = September
| doi = 10.1002/ajh.10356
| pmid = 12949897
}}</ref>
   
==== Karyotyping: ====
* [[Karyotyping]] can also be used to detect the [[translocation]] t(11;14), which is found in most of [[MCL]] patients.<ref>{{Cite journal
| author = [[Jordi Camps]], [[Itziar Salaverria]], [[Maria J. Garcia]], [[Esther Prat]], [[Silvia Bea]], [[Jessica C. Pole]], [[Lluis Hernandez]], [[Javier Del Rey]], [[Juan Cruz Cigudosa]], [[Marta Bernues]], [[Carlos Caldas]], [[Dolors Colomer]], [[Rosa Miro]] & [[Elias Campo]]
| title = Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines
| journal = [[Leukemia research]]
| volume = 30
| issue = 8
| pages = 923–934
| year = 2006
| month = August
| doi = 10.1016/j.leukres.2005.11.013
| pmid = 16448697
}}</ref>
   
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WH}}
{{WH}}
{{WS}}
{{WS}}

Latest revision as of 05:04, 4 January 2019

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma diagnostic study of choice On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma diagnostic study of choice

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma diagnostic study of choice

on Mantle cell lymphoma diagnostic study of choice

Mantle cell lymphoma diagnostic study of choice in the news

Blogs on Mantle cell lymphoma diagnostic study of choice

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma diagnostic study of choice

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.

Diagnostic Study of Choice

Study of choice

  • Tissue biopsy (nodal or extranodal) is the gold standard test for the diagnosis of mantle cell lymphoma.

Histology

Immunohistochemistry

Fluorescence in situ hybridization (FISH)

Karyotyping:

References

  1. ↑ Francesco Bertoni, Emanuele Zucca & Finbarr E. Cotter (2004). "Molecular basis of mantle cell lymphoma". British journal of haematology. 124 (2): 130–140. PMID 14687022. Unknown parameter |month= ignored (help)
  2. ↑ Chan Yoon Cheah, John F. Seymour & Michael L. Wang (2016). "Mantle Cell Lymphoma". Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34 (11): 1256–1269. doi:10.1200/JCO.2015.63.5904. PMID 26755518. Unknown parameter |month= ignored (help)
  3. ↑ Olaf Determann, Eva Hoster, German Ott, Heinz Wolfram Bernd, Christoph Loddenkemper, Martin Leo Hansmann, Thomas E. F. Barth, Michael Unterhalt, Wolfgang Hiddemann, Martin Dreyling & Wolfram Klapper (2008). "Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group". Blood. 111 (4): 2385–2387. doi:10.1182/blood-2007-10-117010. PMID 18077791. Unknown parameter |month= ignored (help)
  4. ↑ R. Schaffel, C. V. Hedvat, J. Teruya-Feldstein, D. Persky, J. Maragulia, D. Lin, C. S. Portlock, C. H. Moskowitz & A. D. Zelenetz (2010). "Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma". Annals of oncology : official journal of the European Society for Medical Oncology. 21 (1): 133–139. doi:10.1093/annonc/mdp495. PMID 20019090. Unknown parameter |month= ignored (help)
  5. ↑ Tsieh Sun, Mary Lowery Nordberg, James D. Cotelingam, Diana M. Veillon & John Ryder (2003). "Fluorescence in situ hybridization: method of choice for a definitive diagnosis of mantle cell lymphoma". American journal of hematology. 74 (1): 78–84. doi:10.1002/ajh.10356. PMID 12949897. Unknown parameter |month= ignored (help)
  6. ↑ Jordi Camps, Itziar Salaverria, Maria J. Garcia, Esther Prat, Silvia Bea, Jessica C. Pole, Lluis Hernandez, Javier Del Rey, Juan Cruz Cigudosa, Marta Bernues, Carlos Caldas, Dolors Colomer, Rosa Miro & Elias Campo (2006). "Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines". Leukemia research. 30 (8): 923–934. doi:10.1016/j.leukres.2005.11.013. PMID 16448697. Unknown parameter |month= ignored (help)

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Mantle_cell_lymphoma_diagnostic_study_of_choice&oldid=1514391"